Talk:Muscular dystrophy

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
WikiProject Medicine / Medical genetics / Neurology (Rated B-class, Mid-importance)
WikiProject iconThis article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.
B-Class article B  This article has been rated as B-Class on the project's quality scale.
 Mid  This article has been rated as Mid-importance on the project's importance scale.
Taskforce icon
This article is supported by the Medical genetics task force.
Taskforce icon
This article is supported by the Neurology task force (marked as Mid-importance).

Ocrevus - a new treatment[edit]

This article should have the new monoclonal antibody treatment for MS, Ocrevus (Ocrelizumab), to be mentioned in the article, plus link to the Wikipedia article on Ocrelizumab. This Genentech/Roche drug was just recently approved by the FDA. It is the first FDA-approved treatment for the primary progressive form of MS and also approved for the relapse-remitting form. (talk) 17:59, 28 June 2017 (UTC)RMayer

Ref per WP:MEDRS? Doc James (talk · contribs · email) 18:35, 28 June 2017 (UTC)
are there any reviews for this treatment and muscular dystrophy?--Ozzie10aaaa (talk) 18:37, 28 June 2017 (UTC)